These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24618769)

  • 41. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.
    Sharifi M; Lewiecki EM
    Expert Rev Clin Pharmacol; 2014 May; 7(3):281-91. PubMed ID: 24580081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bazedoxifene: a selective estrogen-receptor modulator.
    Mitwally MF
    Womens Health (Lond); 2008 Jul; 4(4):319-26. PubMed ID: 19072496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms.
    Archer DF
    Drugs Aging; 2010 Jul; 27(7):533-44. PubMed ID: 20583848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).
    Lindsay R
    Osteoporos Int; 2011 Feb; 22(2):447-51. PubMed ID: 21069294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
    Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
    JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.
    Carranza-Lira S; Gooch AL; Saldivar N; Osterwalder MS
    Int J Fertil Womens Med; 2007; 52(2-3):93-6. PubMed ID: 18320867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.
    Wild RA; Wu C; Curb JD; Martin LW; Phillips L; Stefanick M; Trevisan M; Manson JE
    Menopause; 2013 Mar; 20(3):254-60. PubMed ID: 23435021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selective estrogen modulators in menopause.
    Gambacciani M
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?
    Falk RT; Manson JE; Barnabei VM; Anderson GL; Brinton LA; Rohan TE; Cauley JA; Chen C; Coburn SB; Pfeiffer RM; Reding KW; Sarto GE; Wentzensen N; Chlebowski RT; Xu X; Trabert B
    Int J Cancer; 2019 Feb; 144(4):730-740. PubMed ID: 30183089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial.
    Ritenbaugh C; Stanford JL; Wu L; Shikany JM; Schoen RE; Stefanick ML; Taylor V; Garland C; Frank G; Lane D; Mason E; McNeeley SG; Ascensao J; Chlebowski RT;
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2609-18. PubMed ID: 18829444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tissue selective estrogen complex (TSEC): a review.
    Pickar JH; Boucher M; Morgenstern D
    Menopause; 2018 Sep; 25(9):1033-1045. PubMed ID: 29533367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
    Gallagher JC; Shi H; Mirkin S; Chines AA
    Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
    Prentice RL; Manson JE; Langer RD; Anderson GL; Pettinger M; Jackson RD; Johnson KC; Kuller LH; Lane DS; Wactawski-Wende J; Brzyski R; Allison M; Ockene J; Sarto G; Rossouw JE
    Am J Epidemiol; 2009 Jul; 170(1):12-23. PubMed ID: 19468079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
    Stefanick ML; Anderson GL; Margolis KL; Hendrix SL; Rodabough RJ; Paskett ED; Lane DS; Hubbell FA; Assaf AR; Sarto GE; Schenken RS; Yasmeen S; Lessin L; Chlebowski RT;
    JAMA; 2006 Apr; 295(14):1647-57. PubMed ID: 16609086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
    Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
    J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
    Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
    JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.
    Black D; Messig M; Yu CR; Assaf AR; Komm BS; Mirkin S; Boucher M
    Menopause; 2016 Apr; 23(4):376-82. PubMed ID: 26694733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
    Umland EM; Karel L; Santoro N
    Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.